METHOD OF PERSONALIZATION OF MEDICAL CARE FOR PATIENTS WITH STOMACH CANCER Russian patent published in 2020 - IPC G01N33/53 A61K31/505 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and can be used for personalized treatment of gastric cancer patients based on a panel of molecular-genetic markers. For this purpose, a patient with suspected gastric cancer at the preoperative stage of the esophagogastroduodenoscopy (EGDS) is subjected to a biopsy and besides the morphological examination of the biopsy material, MLH1, RASSF1A gene methylation, MMP7, hTERT, BIRC5 genes expression, telomerase enzyme activity is evaluated, and if observing high levels of methylation of RASSF1A, MLH1 genes and hTERT gene expression levels more than 0.29, MMP7 gene more than 0.46, BIRC5 gene more than 0.79, as well as telomerase activity more than 24.6, gastric cancer is diagnosed, patient is additionally examined for the purpose of determining the stage and prevalence of the tumor process, the presence of competing and accompanying diseases, as well as polymorphism of TYMS and TP53 genes in blood leukocytes. That is followed by the surgical intervention and / or chemotherapy using fluoropyrimidines, if observing phenotypes 3R / 2R, A6 / A6, 2G / 3C by the TYMS gene and the Arg / Pro phenotype of the TP53 gene in the patient's blood leukocytes and the chemotherapy without including fluoropyrimidines in detecting phenotypes 3R / 3R, 3G / 3G by the TYMS gene and the phenotype Pro / Pro by TP53 gene. Further, if the patient undergoes surgical management, he is under the supervision of an oncologist for follow-up care, and undergoes examinations, wherein the examination involves the control EGDS in period of 6 to 39 months after the operation to obtain a biopsy material from the gastric mucosa and / or stomach stump, in which the level of methylation of N33, CDH1, RANX3 genes is determined, and if abnormal methylation of said genes is detected, a recurrence or general oncology process is predicted. If the patient has not undergone surgical management, then he is under the supervision of an oncologist at follow-up care and undergoes examination after every 2 courses of chemotherapy.

EFFECT: invention provides better results of treating patients with stomach cancer in a shorter period of time with a high percentage of accuracy of diagnosis of stomach cancer; in addition, using the declared molecular-genetic markers enables predicting the effectiveness of the prescribed chemotherapy and reliably predicting the onset of tumor recurrence or general oncology.

1 cl, 3 dwg, 5 ex